Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib | Zendy

Jessica Davies | Zendy; Michael Martinec | Zendy; Paul Delmar | Zendy; Mathieu Coudert | Zendy; Walter Bordogna | Zendy; Sophie Golding | Zendy; Reynaldo Martina | Zendy; Gracy Crane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib

Author(s) -

Jessica Davies,

Michael Martinec,

Paul Delmar,

Mathieu Coudert,

Walter Bordogna,

Sophie Golding,

Reynaldo Martina,

Gracy Crane

Publication year - 2018

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2018-0032

Subject(s) - alectinib , ceritinib , medicine , anaplastic lymphoma kinase , hazard ratio , oncology , lung cancer , clinical trial , proportional hazards model , propensity score matching , confidence interval , malignant pleural effusion

Aim: To compare the overall survival of anaplastic lymphoma kinase-positive non-small-cell lung cancer patients who received alectinib with those who received ceritinib. Materials & methods: Two treatment arms (alectinib [n = 183] and ceritinib [n = 67]) were extracted from clinical trials and an electronic health record database, respectively. Propensity scores were applied to balance baseline characteristics. Kaplan–Meier and multivariate Cox regression were conducted. Results: After propensity score adjustment, baseline characteristics were balanced. Alectinib had a prolonged median overall survival (alectinib = 24.3 months and ceritinib = 15.6 months) and lower risk of death (hazard ratio: 0.65; 95% CI: 0.48–0.88). Conclusion: Alectinib was associated with prolonged overall survival versus ceritinib, which is consistent with efficacy evidence from clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research